ARPO Aerpio Pharmaceuticals Inc.

0.66
+0.03  (+5%)
Previous Close 0.63
Open 0.63
Price To Book 0.64
Market Cap 26,686,613
Shares 40,588,004
Volume 535,865
Short Ratio
Av. Daily Volume 267,410
Stock charts supplied by TradingView

NewsSee all news

  1. Topical Ocular Formulation of Aerpio Pharmaceutical's AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth

  2. Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the

  3. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  4. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  5. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data due 1H 2020.
AKB-4924 (GB004)
Ulcerative Colitis
Phase 2 data released March 18, 2019 did not meet primary endpoint.
AKB-9778 - TIME 2B
Non-Proliferative Diabetic Retinopathy
Further development to continue through partnership.
AKB-9778
Primary open-angle glaucoma (POAG)

Latest News

  1. Topical Ocular Formulation of Aerpio Pharmaceutical's AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth

  2. Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the

  3. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  4. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  5. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  6. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  7. Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced interim results from its